Description: Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
Home Page: www.medigenvac.com
No. 16, Hu Road
Taipei,
114
Taiwan
Phone:
886 2 7745 0830
Officers
| Name | Title |
|---|---|
| Ms. Yu-Ping Yang | Chief Financial Officer |
| Mr. Shih-Shen Lee | Exec. VP of Operations Bus. Unit |
Exchange: TWO
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 72.7273 |
| Price-to-Book MRQ: | 4.7137 |
| Price-to-Sales TTM: | 10.5141 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |